Yu-Zhen Liu

Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial.

Joon-Oh Park, M. Reni, E. Van Cutsem, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.

S. Park, Y. Bang, D. Hodgson, 2017, The Lancet. Oncology.

Development of an Immunohistochemical Assay to Detect the Ataxia-Telangiectasia Mutated (ATM) Protein in Gastric Carcinoma

J. Pugh, D. Balcerzak, L. Pham, 2019, Applied immunohistochemistry & molecular morphology : AIMM.

Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm).

H. Kindler, G. Locker, J. Williams, 2020, Journal of Clinical Oncology.

Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).

N. Clarke, M. Oya, A. Thiery-Vuillemin, 2023, Journal of Clinical Oncology.

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.

M. Oya, N. Mehra, C. Poehlein, 2023, The Lancet. Oncology.